Robert J Kreitman, M.D.
National Cancer Institute (NCI) · National Cancer Institute, National Institutes of Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert J Kreitman, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:40 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04815356 · Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and VariantNational Cancer Institute (NCI) · recruiting · Hairy Cell Leukemia, Hairy Cell Leukemia Variant · principal investigator
- N/ANCT04362865 · Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 InfectionNational Cancer Institute (NCI) · completed · COVID-19 · principal investigator
- Ph2NCT04324112 · Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCLNational Cancer Institute (NCI) · active not recruiting · Hairy Cell Leukemia · principal investigator
- Ph2NCT04322383 · Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantNational Cancer Institute (NCI) · recruiting · Hairy Cell Leukemia · principal investigator
- Ph1NCT03805932 · Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI) · active not recruiting · Hairy Cell Leukemia · principal investigator
- N/ANCT01087333 · Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer TreatmentNational Cancer Institute (NCI) · recruiting · Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL) · principal investigator
- Ph2NCT01059786 · Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaNational Cancer Institute (NCI) · active not recruiting · Hairy Cell Leukemia · principal investigator
- Ph1/Ph2NCT00924170 · Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell LeukemiaNational Cancer Institute (NCI) · completed · Adult T-Cell Leukemia (ATL) · principal investigator
- Ph2NCT00924040 · Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell LeukemiaNational Cancer Institute (NCI) · terminated · Hairy Cell Leukemia · principal investigator
- Ph2NCT00923013 · Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell LeukemiaNational Cancer Institute (NCI) · active not recruiting · Hairy Cell Leukemia · principal investigator
- Ph2NCT00321555 · LMB-2 to Treat Hairy Cell LeukemiaNational Cancer Institute (NCI) · completed · Hairy Cell Leukemia · principal investigator
- Ph2NCT00080535 · Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell LymphomasNational Cancer Institute (NCI) · completed · Lymphoma, T-Cell, Cutaneous · principal investigator
- Ph2NCT00077922 · Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI) · completed · Leukemia, Lymphocytic, Chronic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 8 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.